Top analyst sizes up windfall billions for Pfizer, Regeneron and Eli Lilly in a big week for the Covid-19 R&D race
Pfizer CEO Albert Bourla’s $5.6 million personal windfall from stock sales on the same day the pharma giant exhilarated much of the world with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
